The UK is the first country to introduce a dedicated law to decentralise manufacturing of personalised medicines at the point ...

AstraZeneca has announced $50bn investment plans in the US by 2030 for drug manufacturing and research and development (R&D).

Sanofi has signed an agreement to acquire Vicebio’s share capital for $1.15bn upfront, to expand its vaccine development capabilities.

Sarepta CEO Doug Ingram said it is important the company maintains a “positive working relationship” with the FDA.

Biogen has announced plans to invest an additional $2bn in Research Triangle Park (RTP) in the US state of North Carolina. The latest manufacturing investment will support the ongoing development of ...

Fangzhou has signed a MoU with Novo Nordisk to collaborate on the management of serious chronic diseases, including obesity and diabetes.

Sanofi has completed its acquisition of Blueprint, enhancing its portfolio with a commercialised therapy and expertise focused on SM.

Now is the time to invest in quantum literacy, explore proof-of-concept collaborations and monitor quantum’s integration.

Life sciences venture capital (VC) firm Omega Funds has closed its eighth fund, with capital commitments totalling $647m.

The US Food and Drug Administration (FDA) has approved GSK's Shingrix vaccine (recombinant zoster vaccine or RZV) in a prefilled syringe presentation to prevent shingles (herpes zoster). This ...

A successful monoclonal antibody could undergo scale-up several times across the span of its commercial life, each stage presenting new complexities during sterile fill-finish. As more sponsors turn ...

Astellas Pharma has entered a memorandum of understanding (MoU) with the Korea Institute of Startup and Entrepreneurship Development (KISED) to support Korean pharmaceutical startups' global growth.